Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
HER2-позитивная диссеминированная аденокарцинома желудка и пищеводно-желудочного перехода: прогноз, клиническое течение, лечение
HER2-позитивная диссеминированная аденокарцинома желудка и пищеводно-желудочного перехода: прогноз, клиническое течение, лечение
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Основным методом лечения пациентов с раком желудка является лекарственный. Трастузумаб доказал свою эффективность в лечении HER2-позитивного диссеминированного рака желудка при назначении в комбинации со стандартной химиотерапией. Добавление трастузумаба к химиотерапии достоверно увеличивает общую выживаемость и, следовательно, является обязательным для лечения данной категории больных.
Ключевые слова: HER2-положительный рак желудка и пищеводно-желудочного перехода, HER2-статус, трастузумаб, таргетная терапия.
Key words: HER2-positive gastric and gastro-oesophageal junction cancer, HER2-status, trastuzumab, target therapy.
Ключевые слова: HER2-положительный рак желудка и пищеводно-желудочного перехода, HER2-статус, трастузумаб, таргетная терапия.
________________________________________________
Key words: HER2-positive gastric and gastro-oesophageal junction cancer, HER2-status, trastuzumab, target therapy.
Полный текст
Список литературы
1. Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2010; 3: CD004064. DOI: http://10.1002/14651858.CD004064.pub3
2. Ajani JA, Rodriquez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. JCO 2009; 27: 15s (Suppl., abstr. 4511).
3. Kang Y, Kang WK, Shin DB et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion jo 5-FU/cisplatin (FP) as first-line therapy in patient with advanced gastric cancer: Efficacy and safety results. J Clin Oncol 2006; 24: 18S. Abstr. 4018.
4. Dank M, Zaluski J, Barone C et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st – line advanced gastric cancer patients. Proc Am Soc Clin Oncol 2005; 23 (16s): 308s. Abstr. 4003.
5. Ajani JA, Podor M, van Cutsem E et al. Multinational randomised phase 11 trial of docetaxel (T) and cisplatin with or without 5-fluorouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC). Proc Am Soc Clin Oncol 2000; 19: 247a (Abstr. 957).
6. Cunnigham D, Rao S, Starling N et al. Randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: The REAL 2 trial. J Clin Oncol; 24: 18S. Abstr. 4001.
7. Bass AJ. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; http://doi:10.1038/nature13480
8. Tan IB, Ivanova T, Lim KH et al. Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology 2011; 141: 476–85.
9. Ung L, Chua TC, Merrett ND. Targeting HER2-amplifications in gastric cancer. Gastrointestinal Cancer: Targets Therapy 2014; 4: 11–22.
10. Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy vs. chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687–97.
11. Bang Y-J. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. J Clin Oncol 2012; 30: (suppl. 34; abstr. 11).
12. Hecht JR et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. JCO 2013 ASCO Annual Meeting Abstracts 2013; 31 (18). Suppl. LBA4001.
2. Ajani JA, Rodriquez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. JCO 2009; 27: 15s (Suppl., abstr. 4511).
3. Kang Y, Kang WK, Shin DB et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion jo 5-FU/cisplatin (FP) as first-line therapy in patient with advanced gastric cancer: Efficacy and safety results. J Clin Oncol 2006; 24: 18S. Abstr. 4018.
4. Dank M, Zaluski J, Barone C et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st – line advanced gastric cancer patients. Proc Am Soc Clin Oncol 2005; 23 (16s): 308s. Abstr. 4003.
5. Ajani JA, Podor M, van Cutsem E et al. Multinational randomised phase 11 trial of docetaxel (T) and cisplatin with or without 5-fluorouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC). Proc Am Soc Clin Oncol 2000; 19: 247a (Abstr. 957).
6. Cunnigham D, Rao S, Starling N et al. Randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: The REAL 2 trial. J Clin Oncol; 24: 18S. Abstr. 4001.
7. Bass AJ. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; http://doi:10.1038/nature13480
8. Tan IB, Ivanova T, Lim KH et al. Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology 2011; 141: 476–85.
9. Ung L, Chua TC, Merrett ND. Targeting HER2-amplifications in gastric cancer. Gastrointestinal Cancer: Targets Therapy 2014; 4: 11–22.
10. Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy vs. chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687–97.
11. Bang Y-J. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. J Clin Oncol 2012; 30: (suppl. 34; abstr. 11).
12. Hecht JR et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. JCO 2013 ASCO Annual Meeting Abstracts 2013; 31 (18). Suppl. LBA4001.
Авторы
Н.С.Бесова
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.